Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Deepa Jagadeesh et al.|The Lancet Haematology|2024Cited by 37
How, when and where current mass flows in Martian gullies are driven by CO2 sublimationLonneke Roelofs, Manish Patel|Communications Earth & Environment|2024Cited by 7